Session: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
CML, Chronic Myeloid Malignancies, Diseases, Myeloid Malignancies
Objective To validate the predictive performance of the imatinib-therapy failure (IMTF) score and compare the predictive discrimination of IMTF score with ELTS score in newly-diagnosed children with chronic phase CML receiving imatinib-therapy.
Methods Data of children with chronic phase CML diagnosed at < 18 years receiving initial imatinib (260 to 340 mg/m2 daily) from January 2006 to December 2023 were analyzed. Diagnosis, monitoring and treatment response assessment were according to ELN recommendations. The cumulative incidence of therapy response and imatinib-therapy failure by IMTF score and ELTS score was calculated using the Fine-Gray test considering competing events defined as stopping imatinib-therapy, a switch to a 2nd or 3rd generation TKIs, a transplant or death unrelated to CML. FFS, PFS and OS were calculated by Kaplan-Meier method with the log-rank test.
Results A total of 324 children were included in this study. 196 (61%) were male. Median age at diagnosis was 13 years (IQR, 9-17 years). 298 (92%) patients achieved a CHR by 3 months. With a median follow-up of 77 months (IQR, 51-107 months) for survivor, the incidences of CCyR, MMR, MR4.0 and MR4.5 at 8 years were 96% (94, 98%), 84% (79, 88%), 60% (53, 67%), and 45% (38, 53%); the 8-year probabilities of FFS, PFS and survival were 80% (75, 84%), 92% (88, 95%), 97% (95, 99%), respectively. By IMTF score, 63 (19%), 62 (19%), 103 (32%), 67 (21%), and 29 (9%) children were classified as very low-, low-, intermediate-, high-, and very high-risk groups. Since there was no significant difference between the low- and intermediate-risk groups (p = 0.941), these groups were combined into a integrated low/intermediate risk group. In the very low-, low/intermediate-, high- and very high risk groups, the 8-year cumulative incidences of imatinib-therapy failure were 5% (0,11%), 18% (12, 24%), 30% (18, 41%) and 43% (24, 62%; p < 0.001). There were significant differences in imatinib-therapy failure rate among the very low-, low/intermediate- and high-risk groups (p < 0.001 - 0.036), but not between the high and very high-risk groups (p = 0.184). By ELTS score, the 8-year cumulative incidences of imatinib-therapy failure in the low- (n = 223, 69%), intermediate-(n = 81, 25%) and high risk group (n = 20, 6%) were 14% (9, 19%), 32% (22, 43%) and 36% (14, 58%) (p < 0.001), but no significant difference between the intermediate- and high risk group were observed (p = 0.590). The IMTF score exhibited a higher C-statistic values of 0.680 than the ELTS score (0.644).
Conclusion IMTF score had better predictive discrimination for imatinib-therapy failure in children with CML-CP compared to ELTS score.
Disclosures: No relevant conflicts of interest to declare.
See more of: Oral and Poster Abstracts